ESLA
Estrella Immunopharma, Inc.
Price Chart
Latest Quote
$0.95
-0.06 (-5.94%)
Current Price
| Previous Close | $1.01 |
| Open | $1.03 |
| Day High | $1.03 |
| Day Low | $0.95 |
| Volume | 51,505 |
Stock Information
| Shares Outstanding | 43.03M |
| Cash Equivalents | $1.93M |
| Net Income | $-13.25M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $40.88M |
| EPS (TTM) | $-0.34 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $38.96M |
| Income | $-13.25M |
| Book/sh | $-0.12 |
| Cash/sh | $0.04 |
Financial Ratios
| Quick Ratio | 0.22 |
| Current Ratio | 0.24 |
Returns & Margins
| ROA | -271.46% |
Ownership
| Insider Ownership | 60.61% |
| Institutional Ownership | 12.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.97 |
| P/B | -7.66 |
Analyst Data
| Recommendation | none |
| Target Price | $12.00 |
Technical Indicators
| SMA20 | $1.09 |
| SMA50 | $1.34 |
| SMA200 | $1.44 |
| RSI | 36.54 |
| ATR | 0.0974 |
| Shares Float | 14.11M |
| Short Float | 0.49% |
| Short Ratio | 2.58 |
| Volatility | 0.85 |
| Rel Volume | 1.26 |
Performance History
| Week | -12.04% |
| Month | -16.67% |
| Quarter | -13.64% |
| 6 Months | -41.72% |
| YTD | -31.65% |
| Year | +5.56% |
| 3 Years | -91.28% |
| 10 Years | -90.26% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.95 | 51,500 |
| 2026-06-17 | $1.01 | 12,300 |
| 2026-06-16 | $1.00 | 39,600 |
| 2026-06-15 | $1.03 | 40,400 |
| 2026-06-12 | $1.06 | 22,400 |
| 2026-06-11 | $1.08 | 30,200 |
| 2026-06-10 | $1.06 | 30,400 |
| 2026-06-09 | $1.15 | 40,300 |
| 2026-06-08 | $1.13 | 62,600 |
| 2026-06-05 | $1.14 | 6,600 |
| 2026-06-04 | $1.15 | 187,900 |
| 2026-06-03 | $1.04 | 46,300 |
| 2026-06-02 | $1.08 | 6,500 |
| 2026-06-01 | $1.12 | 51,200 |
| 2026-05-29 | $1.09 | 9,200 |
| 2026-05-28 | $1.14 | 51,100 |
| 2026-05-27 | $1.15 | 21,800 |
| 2026-05-26 | $1.15 | 58,000 |
| 2026-05-22 | $1.16 | 27,900 |
| 2026-05-21 | $1.13 | 19,000 |
| 2026-05-20 | $1.14 | 5,700 |
| 2026-05-19 | $1.14 | 25,100 |
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $13,062,674 | $7,310,098 | $11,114,402 | $1,685,347 |
| Operating Expense | $13,062,674 | $7,310,098 | $11,114,402 | $1,685,347 |
| General And Administrative Expense | $2,814,129 | $3,201,173 | $663,190 | $296,248 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Normalized Income | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Net Income From Continuing And Discontinued Operation | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Total Operating Income As Reported | $-13,062,674 | $-7,310,098 | $-11,114,402 | $-1,685,347 |
| Net Income Common Stockholders | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Net Income | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Net Income Including Noncontrolling Interests | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Net Income Continuous Operations | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Pretax Income | $-13,062,674 | $-7,310,098 | $-11,114,402 | $-1,685,347 |
| Operating Income | $-13,062,674 | $-7,310,098 | $-11,114,402 | $-1,685,347 |
| Per Share | ||||
| Diluted EPS | $-0.35 | $-0.27 | $-0.32 | $-0.05 |
| Basic EPS | $-0.35 | $-0.27 | $-0.32 | $-0.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,062,674 | $-7,310,098 | $-11,114,402 | $-1,685,347 |
| EBITDA (Bullshit earnings) | $-13,062,674 | $-7,310,098 | $-11,114,402 | $-1,685,347 |
| EBIT | $-13,062,674 | $-7,310,098 | $-11,114,402 | $-1,685,347 |
| Diluted Average Shares | $36,820,810 | $27,103,964 | $35,201,232 | $35,201,232 |
| Basic Average Shares | $36,820,810 | $27,103,964 | $35,201,232 | $35,201,232 |
| Diluted NI Availto Com Stockholders | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Tax Provision | $838 | $1,625 | $0 | $0 |
| Research And Development | $10,248,545 | $4,108,925 | $10,451,212 | $1,389,099 |
| Selling General And Administration | $2,814,129 | $3,201,173 | $663,190 | $296,248 |
| Other Gand A | $2,814,129 | $3,201,173 | $663,190 | $296,248 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-10,366,058 | $4,273,488 | $-11,742,550 | $-1,039,843 |
| Total Assets | $3,176,975 | $4,454,189 | $3,028,399 | $4,921,666 |
| Total Non Current Assets | $1,500,000 | $0 | $276,187 | $0 |
| Non Current Prepaid Assets | $1,500,000 | $0 | - | - |
| Current Assets | $1,676,975 | $4,454,189 | $2,752,212 | $4,921,666 |
| Receivables | $292,673 | $288,761 | $273,066 | - |
| Other Receivables | $292,673 | $288,761 | - | - |
| Cash Cash Equivalents And Short Term Investments | $1,384,302 | $4,165,428 | $2,479,146 | $4,088,333 |
| Cash And Cash Equivalents | $1,384,302 | $4,165,428 | $2,479,146 | $4,088,333 |
| Non Current Deferred Assets | - | $0 | $276,187 | - |
| Notes Receivable | - | $0 | $273,066 | - |
| Prepaid Assets | - | - | - | $833,333 |
| Cash Financial | - | - | - | $4,088,333 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,543,033 | $180,701 | $14,770,949 | $5,961,509 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $5,012,725 | $5,014,825 |
| Current Liabilities | $13,543,033 | $180,701 | $9,758,224 | $946,684 |
| Other Current Liabilities | $356,505 | - | - | - |
| Payables And Accrued Expenses | $13,186,528 | $180,701 | $9,758,224 | $946,684 |
| Payables | $631,033 | $55,466 | $9,337,443 | $946,684 |
| Other Payable | $57,501 | $347 | - | - |
| Total Tax Payable | $18,751 | $55,119 | $4,297 | $1,097 |
| Income Tax Payable | $0 | $40,744 | $0 | - |
| Accounts Payable | $554,781 | $0 | $9,333,146 | $945,587 |
| Other Non Current Liabilities | - | - | $12,725 | $14,825 |
| Equity | ||||
| Common Stock Equity | $-10,366,058 | $4,273,488 | $-11,742,550 | $-1,039,843 |
| Total Equity Gross Minority Interest | $-10,366,058 | $4,273,488 | $-11,742,550 | $-1,039,843 |
| Stockholders Equity | $-10,366,058 | $4,273,488 | $-11,742,550 | $-1,039,843 |
| Retained Earnings | $-36,990,815 | $-19,500,276 | $-12,188,553 | $-1,074,151 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $5,000,000 | $5,000,000 |
| Preferred Stock Equity | - | - | $5,000,000 | $5,000,000 |
| Other | ||||
| Treasury Shares Number | $515,281 | $321,794 | - | - |
| Ordinary Shares Number | $37,970,938 | $36,289,076 | $35,201,232 | $35,201,232 |
| Share Issued | $38,486,219 | $36,610,870 | $35,201,232 | $35,201,232 |
| Tangible Book Value | $-10,366,058 | $4,273,488 | $-11,742,550 | $-1,039,843 |
| Invested Capital | $-10,366,058 | $4,273,488 | $-11,742,550 | $-1,039,843 |
| Working Capital | $-11,866,058 | $4,273,488 | $-7,006,012 | $3,974,982 |
| Total Capitalization | $-10,366,058 | $4,273,488 | $-11,742,550 | $-1,039,843 |
| Treasury Stock | $598,379 | $354,440 | $0 | - |
| Additional Paid In Capital | $27,219,287 | $24,124,543 | $445,905 | $34,290 |
| Capital Stock | $3,849 | $3,661 | $98 | $18 |
| Common Stock | $3,849 | $3,661 | $98 | $18 |
| Current Accrued Expenses | $12,555,495 | $125,235 | $420,781 | - |
| Preferred Stock | - | $0 | $5,000,000 | $5,000,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,785,679 | $-16,068,306 | $-1,336,121 | $-1,442,028 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,785,679 | $-16,068,306 | $-1,336,121 | $-1,442,028 |
| Cash Flow From Continuing Operating Activities | $-1,785,679 | $-16,068,306 | $-1,336,121 | $-1,442,028 |
| Operating Gains Losses | $38,189 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | - | $4,960,647 | $-273,066 | $0 |
| Cash Flow From Continuing Investing Activities | - | $4,960,647 | $-273,066 | - |
| Net Other Investing Changes | - | $4,960,647 | $-273,066 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-29,462 | $-354,440 | $0 | - |
| Issuance Of Capital Stock | $2,400,000 | $9,020,000 | $0 | $5,000,000 |
| Financing Cash Flow | $2,253,065 | $12,793,941 | $0 | $5,530,361 |
| Cash Flow From Continuing Financing Activities | $2,253,065 | $12,793,941 | $0 | $5,530,361 |
| Net Other Financing Charges | $-117,473 | $4,128,381 | - | - |
| Net Common Stock Issuance | $2,370,538 | $-354,440 | $0 | - |
| Common Stock Issuance | $2,400,000 | $0 | - | - |
| Net Preferred Stock Issuance | - | $9,020,000 | $0 | $5,000,000 |
| Preferred Stock Issuance | - | $9,020,000 | $0 | $5,000,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $2,663 | $0 | $0 |
| Income Tax Paid Supplemental Data | $913 | $1,600 | $0 | $0 |
| End Cash Position | $1,384,302 | $4,165,428 | $2,479,146 | $4,088,333 |
| Beginning Cash Position | $916,916 | $2,479,146 | $4,088,333 | $0 |
| Changes In Cash | $467,386 | $1,686,282 | $-1,609,187 | - |
| Common Stock Payments | $-29,462 | $-354,440 | $0 | - |
| Change In Working Capital | $10,620,670 | $-9,951,236 | $9,368,686 | $113,351 |
| Change In Payables And Accrued Expense | $10,189,482 | $-9,801,242 | $8,535,353 | $946,684 |
| Change In Accrued Expense | $9,606,666 | $-18,000 | $22,000 | $945,587 |
| Change In Payable | $582,816 | $-9,783,242 | $8,513,353 | - |
| Change In Account Payable | $550,346 | $-9,333,146 | $8,387,559 | - |
| Change In Tax Payable | $-4,184 | $-138 | $3,200 | $1,097 |
| Change In Income Tax Payable | $-4,184 | $-138 | $3,200 | $1,097 |
| Change In Prepaid Assets | $431,188 | $-149,994 | $833,333 | $-833,333 |
| Stock Based Compensation | $618,974 | $1,194,653 | $409,595 | $129,968 |
| Gain Loss On Investment Securities | $38,189 | - | - | - |
| Net Income From Continuing Operations | $-13,063,512 | $-7,311,723 | $-11,114,402 | $-1,685,347 |
| Repayment Of Debt | - | $-300,000 | $0 | - |
| Issuance Of Debt | - | $300,000 | $0 | - |
| Net Issuance Payments Of Debt | - | $0 | $0 | - |
| Net Short Term Debt Issuance | - | $0 | - | - |
| Short Term Debt Payments | - | $-300,000 | - | - |
| Short Term Debt Issuance | - | $300,000 | - | - |
| Net Long Term Debt Issuance | - | $0 | $0 | - |
| Long Term Debt Payments | - | $-300,000 | $0 | - |
| Long Term Debt Issuance | - | $300,000 | $0 | - |
| Proceeds From Stock Option Exercised | - | - | - | $15,000 |
Fetched: 2026-06-20